Amlan International Names Beijing Zhongnong Pasture Biotechnology Co., Ltd. as Master Distributor in China
CHICAGO, June 01, 2023 (GLOBE NEWSWIRE) -- Amlan® International, the animal health business of Oil-Dri® Corporation of America and a global leader in mineral-based feed additives that optimize the intestinal health of poultry and livestock, is proud to announce its strategic restructuring plans for the China business. To streamline distribution and increase efficiency, Amlan has chosen Beijing Zhongnong Pasture Biotechnology Co., Ltd. as its master distributor in China.
The strategic decision recognizes the significance of the Chinese market and Amlan’s successful longstanding partnership with Zhongnong. In 2021, China had the world’s largest swine meat production, 53 million MT, producing 44% of global production. Additionally, China was the world’s second largest broiler meat producer, producing 14.7 million MT, and the world’s third largest milk producer, producing 36.8 million MT in the same year. With nearly 20 years of experience serving the Chinese feed and farming industry, Zhongnong has proven to be a valuable partner in the northern region of China by working closely with Amlan to provide proven mineral-based feed additives to Chinese animal producers.
Zhongnong has a highly professional sales team with widespread reach and a comprehensive service network, possessing an in-depth understanding and appreciation of Amlan's products. Leveraging this vast knowledge and industry experience will enhance the value delivered to customers in the Chinese market by improving distribution efficiency and promoting Amlan's full range of products, including Calibrin®-A and Calibrin®-Z products, and products, such as Varium® and NeoPrime®, that will be available in the future. Since 2012, Zhongnong has been one of Amlan’s top-performing distributors, fostering a long history of partnership, mutual trust, and support. Amlan and Zhongnong have full confidence in the market and sales prospects.
"We are extremely optimistic about Amlan's future prospects for global growth. Zhongnong has a distinct advantage in the China market with a strong and loyal ruminant and layer customer base that can accelerate Amlan’s business opportunities and support the business," said Dr. Wade Robey, Vice President of Agriculture, Oil-Dri Corporation of America, and President, Amlan International. By establishing Zhongnong as its master distributor, Amlan is poised to continue its growth and success in the Chinese market while providing value and support to both existing and future customers.
Company Information
Oil-Dri Corporation of America doing business as “Amlan International” is a publicly traded company on the New York Stock Exchange (NYSE: ODC). Oil-Dri leverages over 80 years of expertise in mineral science to selectively mine and process their unique mineral for consumer and business-to-business markets. Amlan International sells feed additives across the world.
Product availability may vary by country, associated claims do not constitute medical claims and may differ based on government requirements.
Media Contact
Reagan Culbertson
VP, Strategic Marketing
Press@amlan.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5f47053e-1736-4253-8861-6e1c8eddf6be
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Nyxoah Strengthens its Executive Leadership Team28.11.2023 22:30:00 CET | Press release
Nyxoah Strengthens its Executive Leadership Team Francis Kim appointed as Chief Regulatory and Quality Officer Mont-Saint-Guibert, Belgium – November 28, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Francis Kim as Chief Regulatory and Quality Officer. Francis will be leading Nyxoah’s Global Regulatory and Quality departments. Francis is a highly experienced global regulatory and quality executive in the healthcare industry, having spent more than 25 years in the medical device and life sciences sector. Francis has led Regulatory and Quality departments at Medtronic, Philips, and other companies, including introducing several innovative products and therapies to the market. “Nyxoah is entering the most exciting time in the Company’s history, with data fro
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update28.11.2023 22:15:00 CET | Press release
Product revenue for the nine months of 2023 increased to $29.8 million, compared to $11.1 million for the same period in 2022Marketing authorization was received for AVT04 in Canada and Japan, the first for a biosimilar to Stelara® (ustekinumab)The European Medicines Agency proposed market authorization for AVT04 in the 30 member states of the European Economic Area, pending a final decision by the European CommissionApprovability of AVT02 and AVT04 in the U.S. now pending satisfactory US Food and Drug Administration (FDA) inspection of Alvotech’s facility in Iceland, currently expected on January 10 – 19, 2024Management will conduct a business update conference call and live webcast on Thursday November 29, 2023, at 8:00 am ET (13:00 pm GMT) Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first nine months of 2023 and pr
RÄTTELSE: Saknad MAR-etikett i tidigare pressmeddelande – ”Anoto ingår ett avtal för 1,1 miljoner USD avseende försäljning av pennor och treåriga mjukvarulicenser med Deutsche Telekom”28.11.2023 19:15:00 CET | Pressemelding
Anoto Group AB (publ) utfärdar en rättelse av pressmeddelandet som publicerades tidigare idag. Rättelsen avser att pressmeddelandet saknade MAR-etikett med hänvisning till EU:s marknadsmissbruksförordning (MAR). Följande information skulle ha varit med i pressmeddelandet: ”Denna information är sådan information som Anoto Group AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades genom ovanstående kontaktpersons försorg för offentliggörande den 28 november 2023, kl. 08:00 CEST.” Nedan publiceras det korrekta pressmeddelandet i sin helhet. Stockholm den 28 november 2023 – Anoto Group AB (publ) ("Anoto" eller "Bolaget") meddelar idag att bolaget har tecknat ett upphandlingsavtal som avser försäljning av nya pennor, samt ett treårigt mjukvarulicensavtal med Deutsche Telekom AG (”Deutsche Telekom”). Deutsche Telekom är en av de äldsta kunderna inom Anotos affärssegment Forms och avtalet innebär att ramverket inom vilket Anoto och Deutsche T
CORRECTION: Missing MAR label in previous press release – “Anoto enters into a USD 1.1 million agreement for the sale of pens and three-year software licenses with Deutsche Telekom”28.11.2023 19:15:00 CET | Press release
Anoto Group AB (publ) issues a correction to the press release published earlier today. The correction refers to the fact that the press release lacked a MAR label with reference to the EU Market Abuse Regulation (MAR). The following information should have been included in the press release: ”This information constitutes inside information as Anoto Group AB (publ) is obliged to disclose under the EU Market Abuse Regulation 596/2014. The information was provided by the contact person above for publication 28 November 2023, at 08:00 CEST.” The correct press release is published in its entirety below. Stockholm, 28 November 2023 – Anoto Group AB (publ) ("Anoto" or the "Company") today announces that it has signed a procurement agreement relating to the sale of new pens, plus a new three-year software licensing agreement with Deutsche Telekom AG (“Deutsche Telekom”). Deutsche Telekom is one of the oldest customers of Anoto’s Forms business and this agreement means that the framework withi
Status for Selskabets tilgodehavende hos Portinho S.A.28.11.2023 18:30:48 CET | pressemeddelelse
28. november 2023 Meddelelse nr. 46 Status for Selskabets tilgodehavende hos Portinho S.A. Selskabets bestyrelse, valgt ind i forbindelse med at Selskabet blev omdannet til en lægemiddelvirksomhed, og direktion har i længere tid, haft en meget tæt dialog med ledelsen i Portinho S.A. om indfrielse af Selskabets tilgodehavende hos Portinho S.A., der stammer fra tiden før Selskabet blev omdannet til en lægemiddelvirksomhed. Selskabets bestyrelse og direktion har sideløbende allokeret betydelige ressourcer til at afdække, hvilke dispositioner der fra den tidligere ledelse oprindeligt førte til etableringen af tilgodehavendet samt rationalet for de efterfølgende dispositioner af den tidligere ledelse, der har indvirket på tilgodehavendets vandring. Dette arbejde pågår forsat med blandt andet bistand fra både dansk og portugisisk juridisk rådgiver. Omfanget og vurderingen af de foreløbige resultater af undersøgelsesarbejdet har ført til, at det ikke længere er Selskabets vurdering, at tilgod